His third question is whether cannabis serves as a gateway drug. There are two possibilities. The first is that marijuana activates certain behavioral and neurological pathways that ease the onset of more serious addictions. The second possibility is that marijuana offers a safer alternative to other drugs: that if you start smoking pot to deal with chronic pain you never graduate to opioids.
Sleep is an essential component to maintaining health. In children, sleep is also vital for growth and development. Ongoing sleep deprivation has been linked to an increased risk for some chronic health problems. In addition, sleep deprivation has been shown to correlate with both increased susceptibility to illness and slower recovery times from illness. In one study, people with chronic insufficient sleep, set as six hours of sleep a night or less, were found to be four times more likely to catch a cold compared to those who reported sleeping for seven hours or more a night. Due to the role of sleep in regulating metabolism, insufficient sleep may also play a role in weight gain or, conversely, in impeding weight loss. Additionally, in 2007, the International Agency for Research on Cancer, which is the cancer research agency for the World Health Organization, declared that "shiftwork that involves circadian disruption is probably carcinogenic to humans," speaking to the dangers of long-term nighttime work due to its intrusion on sleep. In 2015, the National Sleep Foundation released updated recommendations for sleep duration requirements based on age and concluded that "Individuals who habitually sleep outside the normal range may be exhibiting signs or symptoms of serious health problems or, if done volitionally, may be compromising their health and well-being."
Without arguing the merits of the above contentions, we point out that the legitimate use of hemp for non-intoxicant purposes has been inhibited by the continuing ferocious war against drug abuse. In this atmosphere, objective analysis has often been lacking. Unfortunately both proponents and opponents have tended to engage in exaggeration. Increasingly, however, the world is testing the potential of hemp in the field and marketplace, which surely must be the ultimate arbiters. De Guzman (2001), noting the pessimistic USDA report, observed that “Nevertheless, others point to the potential of [the] market. Hemp products have a growing niche market of their own, and the market will remain healthy and be well supported with many competing brands.”
To my understanding, neither CBD nor THC are effective for “severe” pain; rather, they work better for mild to moderate chronic pain. Often, with severe pain, the dosage of opiates can be decreased with concomitant use of medical cannabis or CBD and that decrease in dose makes their use safer. Concurrent use of THC does increase the analgesic effect of CBD, but it also adds the “high” which some people do not want as a side effect.
For example, smoking pot is widely supposed to diminish the nausea associated with chemotherapy. But, the panel pointed out, “there are no good-quality randomized trials investigating this option.” We have evidence for marijuana as a treatment for pain, but “very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.” The caveats continue. Is it good for epilepsy? “Insufficient evidence.” Tourette’s syndrome? Limited evidence. A.L.S., Huntington’s, and Parkinson’s? Insufficient evidence. Irritable-bowel syndrome? Insufficient evidence. Dementia and glaucoma? Probably not. Anxiety? Maybe. Depression? Probably not.
In support of the previous study by Power et al. (in press), a second study by Giordano, Ohlsoon, Sundquist, Sundquist, and Kendler (2015) found that the relationship between cannabis use or abuse and schizophrenia may not be as strong as believed. The authors found that as the degree of shared genetic and environmental factors increased (beginning with first cousins to full siblings), the relationship between schizophrenia and cannabis abuse decreased, although it remained significant even in full sibling pairs.
The legality of CBD in the US varies from state to state, but at the federal level, CBD is mysteriously classified as a Schedule I drug despite its sourcing. According to the federal government, Schedule I drugs are substances or chemicals with no currently accepted medical use and a high potential for abuse. Other Schedule I drugs include heroin, LSD, marijuana, and ecstasy. However, CBD can be purchased as a dietary supplement throughout the country despite the FDA’s official stance that CBD isn’t a supplement. The landscape of CBD legality in the US is exactly as confusing as it reads; that squirrely, perplexing itch at the back of your brain is cognitive dissonance, and it’s an entirely normal reaction.
In 1988, the first cannabinoid receptor was identified (CB1) (Howlett et al 1988) and in 1993, a second was described (CB2) (Munro et al 1993). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB1 is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord (Herkenham et al 1990; Hohmann et al 1999), as well as the peripheral nervous system (Fox et al 2001; Dogrul et al 2003) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated (Dogrul et al 2003). CB2, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes (Mackie 2006). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain (Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands (“endocannabinoids”) and metabolizing enzymes comprise the endocannabinoid system (ECS) (Di Marzo et al 1998), whose functions have been prosaically termed to be “relax, eat, sleep, forget and protect” (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (Cannabis sativa, C. indica) (THC, CBD and others), opium poppy (Papaver somniferun) (morphine, codeine), chile peppers (eg, Capsicum annuum, C. frutescens, C. chinense) (capsaicin) and willow bark (Salix spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB1 receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see Pacher et al (2006), while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain (Walker and Huang 2002).
The farm bill is a sprawling piece of legislation that sets U.S. government agricultural and food policy for the country and is renewed roughly every five years. This version of the bill places industrial hemp — which is defined as a cannabis plant with under 0.3% of tetrahydrocannabinol, or THC — under the supervision of the Agriculture Department and removes CBD from the purview of the Controlled Substances Act, which covers marijuana. The law also “explicitly” preserved the Food and Drug Administration’s authority to regulate products containing cannabis, or cannabis-derived compounds.
I work well under pressure, but being extremely busy at work has almost made me less productive—I'm constantly distracted by email, Slack, and the people around me, to the point where getting my work done becomes difficult. This week, however, I've found it easier to put my blinders on, block out all distractions (especially social distractions) and focus on one task at a time. I think this is partly related to the lessened anxiety—I feel more frazzled and off task when my anxiety is running high. It almost feels like a newfound sense of clarity and calm that enables me to focus.
Donald Abrams was a member of the committee that reviewed the evidence that went into producing the report, and he said that the studies they reviewed overwhelmingly used pharmaceutically available preparations that contain THC, including dronabinol, nabilone and the whole-plant extract spray nabiximols, which contains equal parts CBD and THC. It’s impossible to know whether the benefits of cannabis can also be obtained from CBD alone, Abrams said, because CBD is just one of 400 chemicals present in the plant. So far, CBD in isolation has been studied in only a handful of randomized, placebo-controlled trials (considered the gold standard of evidence in medical research), and the evidence remains sparse.
CBD edibles are foods and beverages infused with CBD for oral consumption, and they are immensely popular thanks to their delicious taste as well as their soothing effects. From CBD fruit rolls to CBD-infused coffee, CBD edibles include a wide array of shapes, dosages, and mouthwatering flavors. CBD edibles offer an easy and discreet way to never forget your daily dose of CBD. Besides their fun and fruity taste and appearance, Green Roads CBD Edibles offer all the benefits of CBD in a convenient 30-day supply so you’ll never run out whether you need a short-term fix or long-term relief.
Dispensaries are charging 30 bucks and ounce for Hemp Oil so they have no economic incentive to derive the CBD from Marijuana. I found that it was like pulling teeth, just to get the to admit the CBD oil came from Hemp. They isolate the CBD and then add it back to the Oil. This means there is no THC or Terpenes or any of the beneficial compounds found in marijuana.
There are many ways to prepare cannabis for consumption. And while final marijuana products may come in many forms, each aims to provide rich concentrations of the terpenes, cannabinoids, and other desirable compounds the marijuana plant produces. From the simple process of drying and curing marijuana flowers, to the sophisticated chemistry of producing cannabis concentrates, here’s a guide to the most common forms of cannabis.
Perhaps the most important difference between hemp and marijuana is that marijuana – no pun intended – has a high delta-9 tetrahydrocannabinol content, or THC, which supplies the sought-after psychotropic effect, but it’s low in cannabidiol content, or CBD, which has medicinal properties. Hemp is just the opposite, being typically high in CBD and low in THC, meaning it’s not going to get anybody stoned. In fact, clinical studies show that CBD blocks the effect of THC in the nervous system. Both THC and CBD contain cannabinoid, but it’s the amount that needs to examined, because CBD is currently a Schedule 1 controlled substance. That means that at present, there’s currently no permissible medical protocol in the US.
Debate continues with regard to the relationship between cannabis usage and schizophrenia (reviewed (Fride and Russo 2006)). An etiological relationship is not supported by epidemiological data (Degenhardt et al 2003), but if present, should bear relation to dose and length of high exposure. It is likely that lower serum levels of Sativex in therapeutic usage, in conjunction with anti-psychotic properties of CBD (Zuardi and Guimaraes 1997), would minimize risks. Children and adolescents have been excluded from Sativex RCTs to date. SAFEX studies of Sativex have yielded few incidents of thought disorder, paranoia or related complaints.
Very few randomized controlled trials (RCTs) have been conducted using smoked cannabis (Campbell et al 2001) despite many anecdotal claims (Grinspoon and Bakalar 1997). One such study documented slight weight gain in HIV/AIDS subjects with no significant immunological sequelae (Abrams et al 2003). A recent brief trial of smoked cannabis (3.56% THC cigarettes 3 times daily) in HIV-associated neuropathy showed positive results on daily pain, hyperalgesia and 30% pain reduction (vs 15% in placebo) in 50 subjects over a treatment course of only 5 days (Abrams et al 2007) (Table 1). This short clinical trial also demonstrated prominent adverse events associated with intoxication. In Canada, 21 subjects with chronic pain sequentially smoked single inhalations of 25 mg of cannabis (0, 2.5, 6.0, 9.5% THC) via a pipe three times a day for 5 days to assess effects on pain (Ware et al 2007) with results the authors termed “modest”: no changes were observed in acute neuropathic pain scores, and a very low number of subjects noted 30% pain relief at the end of the study (Table 1). Even after political and legal considerations, it remains extremely unlikely that crude cannabis could ever be approved by the FDA as a prescription medicine as outlined in the FDA Botanical Guidance document (Food and Drug Administration 2004; Russo 2006b), due to a lack of rigorous standardization of the drug, an absence of Phase III clinical trials, and pulmonary sequelae (bronchial irritation and cough) associated with smoking (Tashkin 2005). Although cannabis vaporizers reduce potentially carcinogenic polyaromatic hydrocarbons, they have not been totally eliminated by this technology (Gieringer et al 2004; Hazekamp et al 2006).
Public health also takes various actions to limit the health disparities between different areas of the country and, in some cases, the continent or world. One issue is the access of individuals and communities to health care in terms of financial, geographical or socio-cultural constraints to accessing and using services. Applications of the public health system include the areas of maternal and child health, health services administration, emergency response, and prevention and control of infectious and chronic diseases.
It is important to note that the federal government still considers cannabis a dangerous drug and that the illegal distribution and sale of marijuana is a serious crime. Under the Controlled Substances Act (CSA), marijuana is still considered a Schedule 1 drug. Cultivation and distribution of marijuana are felonies; possession for personal use is a misdemeanor; possession of “paraphernalia” is also illegal. Cultivating 100 plants or more carries a mandatory minimum sentence of five years according to federal statutes.
"Legislative history suggests that Congress accepted the name Cannabis sativa L. for the hemp plant, believing it to be the common description within the scientific community.41 This categorization combined all marijuana-producing Cannabis plants.42 Therefore, any hemp plant capable of producing any amount of THC was classified as Cannabis sativa L. under the CSA.43"
CBD strains can be consumed just as you would THC strains. You can smoke or vaporize CBD-rich flower, eat a CBD-infused edible, swallow a CBD oil capsule, apply a CBD lotion, or use a CBD tincture sublingually. Hemp products also contain CBD, though it is a less efficient source and lacks the beneficial chemical diversity of cannabis-derived CBD products (more on that here).
"Following enactment of the 2014 farm bill provision allowing for growing hemp under certain circumstances, several states have quickly been adopting new state laws to allow for cultivation. To date, more than 30 states or territories have enacted or introduced legislation favorable to hemp cultivation (Figure 6). Other states reportedly considering hemp legislation include Alaska, Arizona, Florida, Georgia, Iowa, Kansas, Massachusetts, Mississippi, New Mexico, South Dakota, Texas, and Wisconsin.53 (The status of state actions regarding hemp is changing rapidly, and information differs depending on source.54)
AC/DC: A Sativa-dominant phenotype of Cannatonic, this cultivar boasts one of the highest ratios of CBD to THC, clocking in at 20:1. AC/DC is claimed to help reduce pain, anxiety, depression and migraines while reducing symptoms in patients with epilepsy, some forms of cancer, and multiple sclerosis. This cultivar’s pinene-rich terpene profile offers potent clear-headed pain relief.
In a study whose findings have not yet been published, he and a colleague, Daniel Friedman, found that patients receiving CBD in addition to their usual medicines had 39 percent fewer convulsive seizures than patients who remained on their normal drug regimen. Given that the study included only the most treatment-resistant patients, this is an “excellent response,” Devinsky says.
"The single largest supplier of U.S. imports of raw and processed hemp fiber is China. Other leading country suppliers include Romania, Hungary, India, and other European countries. The single largest source of U.S. imports of hemp seed and oilcake is Canada. The total value of Canada’s exports of hemp seed to the United States has grown significantly in recent years following resolution of a long-standing legal dispute over U.S. imports of hemp foods in late 2004 (see 'Dispute over Hemp Food Imports (1999-2004)'). European countries have also supplied hemp seed and oilcake to the United States."
CBD has some other very important jobs outside of the endocannabinoid system (ECS). For instance, CBD mildly activates one of the brain’s predominant serotonin receptors (5-HT1A), which may explain CBD’s effects on depression and anxiety. It also acts at the peroxisome proliferator activated receptors (PPARs), which halt the proliferation of cancer cells and convey neuro- and cardioprotection. By interacting with a particular PPAR (gamma), CBD could prove to be a promising new way to prevent alzheimer’s disease and other brain disorders.
Hemp is not the same as marijuana. One really has nothing to do with the other. Hemp was made illegal back in the days when cotton was king in the south and southern cotton plantation owners did not want the competition. They lobbied for, and got a law against hemp being grown nationwide. It never had to do with drugs at that time, and still doesn’t. As always, money and government go hand in hand. Now, recently, South Carolina has legalized growing hemp again, which is the only state in 50 to do so. We will hope for more enlightened agri-business legislation across the nation, soon.
The following sketch of hemp cultivation is insufficient to address all of the practical problems that are encountered by hemp growers. Bócsa and Karus (1998) is the best overall presentation of hemp growing available in English. The reader is warned that this book, as well as almost all of the literature on hemp, is very much more concerned with fiber production than oilseed production. McPartland et al. (2000) is the best presentation available on diseases and pests, which fortunately under most circumstances do limited damage. The resource list presented below should be consulted by those wishing to learn about hemp production. Provincial agronomists in Canada now have experience with hemp, and can make local recommendations. Particularly good web documents are: for Ontario (OMAFRA Hemp Series, several documents): www.gov.on.ca/OMAFRA/english/crops/hort/hemp.html); for Manitoba (several documents): www.gov.mb.ca/agriculture/crops/hemp/bko01s00.html; for British Columbia: (BC Ministry of Agriculture and Foods Fact Sheet on Industrial Hemp, prepared by A. Oliver and H. Joynt): www.agf.gov.bc.ca/croplive/plant/horticult/specialty/specialty.htm
Adverse effects of cannabinoids on immune function have been observed in experimental animals at doses 50–100 times the psychoactive level (Cabral 2001). In four patients using herbal cannabis therapeutically for over 20 years, no abnormalities were observed in leukocyte, CD4 or CD8 cell counts (Russo et al 2002). Investigation of MS patients on Cannador revealed no major immune changes (Katona et al 2005), and similarly, none occurred with smoked cannabis in a short-term study of HIV patients (Abrams et al 2003). Hematological measures have been normal in all Sativex RCTs without clinical signs of immune dysfunction.
While there are more unknowns than knowns at this point, Grant says he doesn’t discount all the anecdotal CBD reports. “You hear somebody say, ‘Hey, I gave this to myself and my kid and we feel a lot better,’ and we should never dismiss that kind of information,” he says. He points out that many modern medicines were discovered when researchers followed up on exactly this sort of human trial-and-error evidence. “But we still need to do the studies that confirm whether all the good things are true, and how much to give, and how to give it,” he says. “These are all questions that need to be answered.”
PHOENIX, AZ / ACCESSWIRE / March 6, 2019 / Uptick Newswire Stock Day Podcast welcomed Hemp Inc., (OTC PINK: HEMP) a company that seeks to build a business constituency for the American small farmer, the American veteran, and other groups experiencing the ever-increasing disparity between tapering income and soaring expenses. CEO, Bruce Perlowin, joined Stock Day host Everett Jolly. To begin the interview Perlowin explained that the Company began by demonstrating what can be developed with hemp, particularly in the industrial setting.
Figuring out how much CBD oil to take can feel like trying to navigate through a complicated maze. The sheer volume of CBD brands on the market can create confusion for consumers, and when you take a closer look, it’s not difficult to understand why. Not only do vendors use different source materials (CBD-rich cannabis vs. industrial hemp, different strains, etc.), but they also implement different extraction techniques .